Alvotech Receives FDA Approval For Selarsdi For Moderate To Severe Plaque Psoriasis
Alvotech Receives FDA Approval For Selarsdi For Moderate To Severe Plaque Psoriasis
Alvotech 獲得 FDA 批准 Selarsdi 治療中度至重度斑塊狀牛皮癬
Alvotech receives FDA approval for Selarsdi for moderate to severe plaque psoriasis
Alvotech 獲得 FDA 批准，將 Selarsdi 用於中度至重度斑塊狀牛皮癬
Adult patients with:
成年患者：
- moderate to severe plaque psoriasis (PsO) who are candidates for phototherapy or systemic therapy. (1.1)
- active psoriatic arthritis (PsA). (1.2)
- 適合光療或全身療法的中度至重度斑塊狀牛皮癬 (pSO)。(1.1)
- 活動性銀屑病關節炎 (psA)。(1.2)
Pediatric patients 6 years and older with:
6 歲及以上的兒科患者：
- moderate to severe plaque psoriasis, who are candidates for phototherapy or systemic therapy. (1.1)
- active psoriatic arthritis (PsA). (1.2)
- 中度至重度斑塊狀牛皮癬，適合光療或全身治療。（1.1）
- 活動性銀屑病關節炎 (psA)。(1.2)
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。